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Insight Box
We combined biomaterial platforms, drug screening, and systems biology to identify mechanisms of
extracellular matrix-mediated adaptive resistance to RTK-targeted cancer therapies. Drug response was
significantly varied across biomaterials with altered stiffness, dimensionality, and cell-cell contacts, and
kinome reprogramming was responsible for these differences in drug sensitivity. Screening across many
platforms and applying a systems biology analysis were necessary to identify MEK phosphorylation as
the key factor associated with variation in drug response. This method uncovered the combination
therapy of sorafenib with a MEK inhibitor, which decreased viability on and within biomaterials in vitro, but
was not captured by screening on tissue culture plastic alone. This combination therapy also reduced
tumor burden in vivo, and revealed a promising approach for combating adaptive drug resistance.

Abstract
Traditional drug screening methods lack features of the tumor microenvironment that contribute
to resistance. Most studies examine cell response in a single biomaterial platform in depth, leaving a gap
in understanding how extracellular signals such as stiffness, dimensionality, and cell-cell contacts act
independently or are integrated within a cell to affect either drug sensitivity or resistance. This is critically
important, as adaptive resistance is mediated, at least in part, by the extracellular matrix (ECM) of the
tumor microenvironment. We developed an approach to screen drug responses in cells cultured on 2D
and in 3D biomaterial environments to explore how key features of ECM mediate drug response. This
approach uncovered that cells on 2D hydrogels and spheroids encapsulated in 3D hydrogels were less
responsive to receptor tyrosine kinase (RTK)-targeting drugs sorafenib and lapatinib, but not cytotoxic
drugs, compared to single cells in hydrogels and cells on plastic. We found that transcriptomic differences
between these in vitro models and tumor xenografts did not reveal mechanisms of ECM-mediated
resistance to sorafenib. However, a systems biology analysis of phospho-kinome data uncovered that
variation in MEK phosphorylation was associated with RTK-targeted drug resistance. Using sorafenib as
a model drug, we found that co-administration with a MEK inhibitor decreased ECM-mediated resistance
in vitro and reduced in vivo tumor burden compared to sorafenib alone. In sum, we provide a novel
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strategy for identifying and overcoming ECM-mediated resistance mechanisms by performing drug
screening, phospho-kinome analysis, and systems biology across multiple biomaterial environments.

Introduction
Adaptive resistance poses a significant challenge for targeted drugs as tumor cells can alter their
signaling pathways to bypass the effect of therapeutics. This adaptive signaling occurs quickly and
independently of acquired mutations, making the timing of therapeutics critical to sensitize tumor cells to
drugs via rewiring from an oncogene-addicted state 1. For instance, triple-negative breast cancer cells
treated with a MEK inhibitor undergo a rapid kinome reprogramming of many receptor tyrosine kinases
(RTKs), cytokines, and downstream signaling pathways 2. Inhibition of this adaptive response by lapatinib
prevents downstream Src, FAK, and Akt signaling 3. Mechanistically, kinase inhibitor treatment can
decrease shedding of RTKs, thus enhancing bypass signaling 4. Drug treatment can also cause changes
in the cell cycle, promoting resistance in the quiescent cells adapting to the treatment 5. These examples
demonstrate that quick and widespread changes in signaling can occur in response to anti-cancer drugs.
The tumor microenvironment is a complex, heterocellular system with known roles in modulating
tumor progression and drug response

6.

The extracellular matrix (ECM) is one feature of the

microenvironment that can alter cell signaling and facilitate adaptive resistance. For example, ECM
stiffness can activate RTKs and engage integrin binding to promote cell growth and survival through the
Raf/MEK/ERK and PI3K/Akt/mTOR pathways

7, 8.

Our group and others have employed engineered

biomaterials to elucidate drug resistance in response to biophysical and biochemical stimuli from the
ECM. Two-dimensional (2D) hydrogels allow for the presentation of controlled integrin binding, a
physiological stiffness, and are amenable to drug screening. Three-dimensional (3D) hydrogels also
present physiological dimensionality and biochemistry through matrix degradability, matrix adhesion, and
homotypic or heterotypic cell-cell interactions. No single system can capture all features of the tumor
microenvironment, and complex systems do not allow for isolation of the effect of individual cues. Here,
we propose a biomaterial-based method to systematically vary stiffness, dimensionality, and cell-cell
contacts to analyze matrix-mediated adaptive resistance by measuring genetic and phospho-signaling
changes.
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All of these extracellular cues can alter the signaling networks targeted by cancer therapeutics.
For example, β1 integrin-mediated tolerance to a BRAF inhibitor in vivo can be recapitulated by stiff
synthetic matrices in vitro 9. We recently developed a high-throughput drug screening platform based on a
poly(ethylene glycol)-phosphorylcholine (PEG-PC) hydrogel and identified that increased substrate
stiffness imparts resistance to sorafenib

10, 11.

Similarly, others have demonstrated decreased drug

sensitivity in 3D hydrogels compared to 2D hydrogels and tissue culture polystyrene (TCPS)

12.

These

studies demonstrate the vast opportunities synthetic biomaterials provide for exploring drug resistance
and rewiring mediated by features of the ECM but have yet to capitalize on the potential for a systematic
analysis of stiffness, geometry, and cell-cell contacts afforded by such systems to understand
mechanisms of ECM-mediated resistance.
It is imperative to consider multiple components of the ECM while studying drug response, as
variations in matrix complexity can produce considerably different predictions for in vivo drug response to
anti-cancer drugs. Since no single system can capture all features of the tumor ECM, we investigated
drug resistance and adaptive reprogramming of breast cancer cells across multiple biomaterial
microenvironments to analyze the genetic and phospho-signaling contributions to adaptive resistance.
Multiple linear regression modeling revealed that MEK signaling explained the difference in RTK-targeted
drug response across the ECMs, and co-administering a MEK inhibitor with sorafenib improved efficacy of
the single agent in vitro and in vivo. This is the first report to combine systems biology analysis with
screening across biomaterial platforms to identify MEK as a mediator of ECM-driven resistance to RTK
inhibitors.

Materials and Methods
Cell culture
All supplies were purchased from Thermo Fisher Scientific (Waltham, MA) unless otherwise noted.
Human breast cancer cell lines MDA-MB-231 and SkBr3 cells were generous gifts from Dr. Sallie Smith
Schneider at the Pioneer Valley Life Sciences Institute and Dr. Shannon Hughes at the Massachusetts
Institute of Technology, respectively, and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
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supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37ºC and 5%
CO2.

Polymerization of 2D and 3D PEG hydrogels
2D PEG-phosphorylcholine (PEG-PC) hydrogels were prepared and protein was coupled as described
previously

10.

Glass-bottom 96-well plates (no. 1.5 coverslip glass; In Vitro Scientific, Sunnyvale, CA)

were plasma treated (Harrick Plasma, Ithaca, NY) and subsequently methacrylate-silanized with 2 vol %
3-(trimethoxysilyl) propyl methacrylate (Sigma-Aldrich, St. Louis, MO) in 95% ethanol (pH 5.0) for 5 min,
washed 3 times with 100% ethanol, and dried at 40°C for 30 minutes. PEGDMA (Mn 750, Sigma-Aldrich),
is added at 1.1 wt % (10 kPa, 0.015 M) or 3.2 wt % (33 kPa, 0.043 M) to a solution of 17 wt % 2methacryloyloxyethyl phosphorylcholine (PC) (Sigma-Aldrich) in phosphate-buffered saline (PBS).
Solutions were sterilized with a 0.2 μm syringe filter (Thermo) and degassed by nitrogen sparging for 30
seconds. Free-radical polymerization was induced by addition of 0.05 wt % ammonium persulfate (APS,
Bio-Rad Laboratories, Hercules, CA) and 0.125 vol % tetramethylethylenediamine (TEMED, SigmaAldrich). Hydrogels of 40 μL per well in the 96-well plates were polymerized under nitrogen for 30
minutes. Post-polymerization, hydrogels were allowed to swell for 24 hours in PBS, then treated with 100
μL of sulfo-SANPAH (ProteoChem, Denver, CO; 0.6 mg/mL in pH 8.5 HEPES buffer) under UV light for
20 minutes, rinsed twice with HEPES buffer, and followed immediately by incubation with type I collagen
at 3.3 μg/cm2 (Thermo) overnight.
3D PEG-maleimide (PEG-MAL) hydrogels were prepared at 10 wt % (3 kPa) and 20 wt % (5 kPa)
solution with a 20K 4-arm PEG-MAL (Jenkem Technology, Plano, TX) and 2mM of the cell binding
peptide CRGD (Genscript, Piscataway, NJ), and was crosslinked at a 1:1 ratio with 1K linear PEG-dithiol
(Sigma-Aldrich) in 2mM triethanolamine (pH ~ 7.4)

13.

Hydrogels were polymerized in 10 μL volumes for 5

minutes before swelling in cell culture medium.
Bulk diffusion of Rhodamine 6G (R6G) (Stokes’ radius 0.76 nm, Sigma-Aldrich) in 3D PEG-MAL
hydrogels was measured by encapsulating 0.1 g/L R6G in the hydrogel and sampling the supernatant at
5-minute intervals. The samples were analyzed on a fluorescent plate reader at excitation: 526
nm/emission: 555nm. The diffusion coefficient of R6G was calculated using the Stokes’-Einstein equation.

5

Formation of uniform tumor spheroids
Lyophilized poly(N-isopropylacryamide)-poly(ethylene glycol) (polyNIPAAM, Cosmo Bio USA, Carlsbad,
CA) was reconstituted in cell culture medium according to the manufacturer’s instructions and kept at 4ºC
until use. Cells were suspended in polyNIPAAM solution placed on ice at a density of 100,000 cells/mL
for SkBr3 cells and 167,000 cells/mL for MDA-MB-231 cells, and each gel was made at a volume of 150
μL. Gelation occurred after 5 minutes at 37ºC, and gels were swollen in cell culture medium. Single cells
were grown into spheroids for 14 days in the gels with regular medium changes. Spheroids were either
dissociated back onto TCPS (for RNA-Seq and drug dosing) or encapsulated in 3D PEG-MAL gels (for
RNA-Seq, drug dosing, and signaling) for 24 hours.

Hydrogel mechanical characterization
Mechanical compression testing for 2D and 3D hydrogels was performed with a TA Instruments AR-2000
rheometer (New Castle, DE) at a 2 μm/s strain rate and analysis as previously described

11.

Indentation

testing for polyNIPAAM hydrogels was performed using a custom-built instrument previously described

14.

For this application, a flat punch probe with a diameter of 1.5 mm was applied to samples at a fixed
displacement rate of 5 μm/s, for maximum displacement of 100 μm. PolyNIPAAM samples were placed
on a heated surface to maintain a sample temperature between 37-40°C throughout testing.

Quantification of drug response
At 24 hours post-seeding, cells on biomaterials were treated with lapatinib (0-64 μM, LC Laboratories,
Woburn, MA), sorafenib (0-64 μM, LC Laboratories), temsirolimus (0-80 μM, Selleckchem, Houston, TX),
doxorubicin (0-32 μM, LC Laboratories), or dimethyl sulfoxide (DMSO, Sigma-Aldrich) as a vehicle
control. Where noted, inhibitors were included in the medium: PD0325901 (3 μM, Sigma-Aldrich),
SP600125 (20 μM, LC Laboratories). After 48 hours of drug treatment, cell viability was quantified by
CellTiter Glo Luminescent Cell Viability Assay (Promega, Madison, WI), and luminescence was read on a
Biotek Synergy H1 plate reader after incubation for 10 minutes. Separately, at 24 hours, viability of
untreated cells was determined via CellTiter Glo for a measurement of initial seeding density. IC 50 and
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GR50

15

values were calculated using the initial seeding density and drug treated measurements using

GraphPad Prism v6.0h.

Cell seeding on biomaterials
Cells were seeded on and in biomaterial microenvironments in serum-free DMEM (1% P/S, 20 ng/mL of
epidermal growth factor (EGF), R&D Systems, and 20 ng/mL of platelet-derived growth factor BB (PDGFBB), R&D Systems, Minneapolis, MN) or serum containing DMEM (1% P/S and 10% FBS) where noted.
Cells were seeded at 30,000 cells/cm2 on PEG-PC gels and on tissue culture plastic (TCPS), or as single
cells at 500 cells/μL in 3D PEG gels. Spheroids were recovered via addition of cold serum free medium
(1% P/S) on ice for 5 minutes for gel dissolution, and then gravity sedimentation for 30 minutes on ice.
The supernatant was removed and the spheroids collected from each polyNIPAAM gel were resuspended in PEG-MAL solution to make 9 3D hydrogels.

RNAseq
Total RNA was isolated using Gen Elute mammalian total RNA miniprep kit (Sigma-Aldrich). The Illumina
TRUseq RNA kit was used to purify and fragment the mRNA, convert it to cDNA, and barcode and
amplify the strands. Quality and length of the inserts was confirmed with an Agilent Genomics 2100
bioanalyzer, followed by single-end reads on a NextSeq 500 to generate a complete transcriptome from
each sample. Transcripts were aligned to the hg19 human reference genome using the Tuxedo Suite
pathway 16.

Gene Set Enrichment Analysis
Aligned samples were converted to GCT and CLS file formats using useGalaxy.org

17.

Samples were

separated by material condition across both cell lines to determine biomaterial microenvironment-specific
gene categories. GSEA software was used to analyze enriched KEGG pathways as previously described
18,

and pathways with significant enrichment of expressed genes were selected 19.

Multiplex phospho-protein quantification
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Cells were seeded onto 2D hydrogels at 56,600 cells/cm2, or into 3D gels at 200,000 single cells in 20 μl
volume gel. Spheroids were grown for 14 days in polyNIPAAM, and then transferred to 3D PEG-MAL
gels, where spheroids from three polyNIPAAM gels were transferred to four 20 μl 3D PEG-MAL gels.
Samples were seeded in serum free DMEM. After 24 hours, cells were dosed with either 8 μm sorafenib,
8 μm lapatinib, 25 μm temsirolimus, or DMSO control in serum free medium (or serum containing medium
where noted) for 4 hours, then washed once with ice cold PBS and lysed in RIPA buffer supplemented
with protease (EDTA-free protease inhibitor cocktail tablets, 1 tablet in 10 ml, Roche, Indianapolis, IN)
and phosphatase (1x phosphatase inhibitors cocktail-II, Boston Bioproducts, Boston, MA) inhibitors, 1 mM
phenylmethylsulfonyl fluoride (Thermo Fisher Scientific), 5 μg/ml pepstatin A (Thermo Fisher Scientific),
10 μg/ml of leupeptin (Thermo Fisher Scientific), 1 mM sodium pyrophosphate (Thermo Fisher Scientific),
25 mM β-glycerophosphate (Santa Cruz, Dallas, TX). Protein concentration was determined with a BCA
assay (Sigma-Aldrich). PEG-MAL gels were manually dissociated with a pipet tip for 30 seconds after
addition of lysis buffer.
Lysate concentrations were adjusted to 520 μg/ml and then analyzed with the MILLIPLEX MAP
Multi-Pathway Magnetic Bead 9-Plex - Cell Signaling Multiplex Assay (Millipore, Billerica, MA; analytes:
CREB (pS133), ERK (pT185/pY187), NFκB (pS536), JNK (pT183/pY185), p38 (pT180/pY182), p70 S6K
(pT412), STAT3 (pS727), STAT5A/B (pY694/699), Akt (pS473) supplemented with additional EGFR (pan
Tyr) and MEK1 (pS222) beads according to the manufacturer’s instructions, with the exception that beads
and detection antibodies were diluted four-fold. Controls were performed to ensure that samples were
within the linear dynamic range. Data is reported as the Mean Fluorescent Intensity (MFI) or fold change
in MFI relative to the vehicle control.
SkBr3 cells on TCPS, 33 kPa 2D gels, and spheroids in 3 kPa PEG-MAL were serum starved for
24 h and then stimulated with 100 ng/mL of EGF (R&D Systems, Minneapolis, MN), and cell lysates were
collected at 0, 5, 15, 60 minutes, and 24 hours time points. Lysate concentrations were adjusted to 160
μg/mL, and samples were quantified the MILLIPLEX MAP Phospho Mitogenesis RTK Magnetic Bead 7Plex Kit (Millipore; analytes: c-Met/HGFR (panTyr), EGFR (panTyr), ErbB2/HER2 (panTyr), ErbB3/HER3
(panTyr), ErbB4/HER4 (panTyr), IR (panTyr), and IGF1R (panTyr) according to the manufacturer’s
instructions, with the exception that beads and detection antibodies were diluted four-fold.
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Experimental Model And Subject Details
Multiple linear regression modeling was performed using ‘stats::lm’ within R, regressing each
compendium of signaling measurements against the corresponding viability measured in the same
conditions. All relationships were assumed to be additive, and no interaction or intercept terms were
included in the models. Each measurement was z-score normalized before regression. The two-sided pvalues presented were calculated based upon the significance of each parameter being non-zero. The
overall performance of each model (as calculated by the F-statistic) corresponded well to the significance
of individual terms. All code and raw measurements for model development are available on Github
(https://github.com/meyer-lab/Barney-Peyton).

Immunofluorescence and immunohistochemistry
Cells were grown in serum for 24 h in the indicated material condition, fixed, and stained for Ki67. Cells
were serum-starved and stimulated with EGF as described above, and stained according to standard
protocols for total EGFR or HER2. The following antibodies were used for immunofluorescence: Ki67
(ab16667, 1:200, Abcam), EGFR (D38B1, 1:100, Cell Signaling Technology), and HER2 (29D8, 1:200,
Cell Signaling Technology). All tumor samples were fixed and paraffin embedded. Ki67 staining
(ab16667, 1:100, Abcam) was done on 6 μm tissue slices. All Alexa Fluor secondary antibodies (Thermo
Fisher Scientific) were used at 1:500. Samples were imaged on a Zeiss Cell Observer SD (Carl Zeiss AG,
Oberkochen, Germany).

Animal Xenografts
All animal experiments were in accordance with institutional guidelines and approved by the Institutional
Animal Care and Use Committee at the University of Massachusetts Amherst. UMass has an approved
Animal Welfare Assurance (#A3551-01) on file with the NIH Office of Laboratory Animal Welfare. MDAMB-231 cells were suspended in Matrigel (Corning, Corning, NY), and 10 6 cells were subcutaneously
injected into the mammary fat pad of 8-10 week old female NOD scid gamma mice from a breeding
colony. Each mouse was injected with two tumors. All mice were housed in ventilated cages with sterile
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bedding, food, and water. Injected cells were grown in vivo for 7 days then drugs were suspended in
DMSO and administered with an intraperitoneal (IP) injection daily for 14 days using a 27-gauge needle.
Mice received 100 μL of one of five different treatments: vehicle (100% DMSO), sorafenib at 10 mg/kg,
PD0325901 at 10 mg/kg, or a combination of the drugs at 5 or 10 mg/kg each. A minimum of 4 mice were
analyzed for each drug dosing condition, and each tumor was considered one replicate.

Quantification And Statistical Analysis
Prism v5.04 (GraphPad Software) was used to perform unpaired Student's t-test, a one-way analysis of
variance (ANOVA) with a Tukey post-test. A two-way ANOVA determined how the IC50 changed with
respect to material modulus, geometry, and medium condition, with a Bonferroni post-test (GraphPad
Prism v5.04). A two-way ANOVA, performed in R, was used to determine drug contribution to tumor
burden. Data are reported as mean ± standard error, where p ≤ 0.05 is denoted with *, ≤ 0.01 with **, and
≤ 0.001 with ***.

Results
Geometry impacts innate breast cancer cell response to RTK/MAPK-targeting drugs
Distinct differences across in vitro screening methods, including stiffness, dimensionality, and
cell-cell interactions prevent comparisons across existing studies. Therefore, we developed a system to
independently evaluate the effects of both the geometry and stiffness of the microenvironment on breast
cancer cell response to targeted and non-targeted drugs. We measured the GR50 (concentration of drug
which dampens growth by 50%)

15

for four drugs (sorafenib, lapatinib, temsirolimus, and doxorubicin)

across multiple biomaterials: TCPS, a 2D PEG-PC hydrogel, and a 3D PEG-MAL hydrogel with
encapsulated single cells or tumor spheroids (Figure 1a). To create tumor spheroids, single cells were
encapsulated sparsely in polyNIPAAM hydrogels and grown into uniform clonal spheroids over 14 days in
culture (Figure 1b-d). This 14 day endpoint achieves a relatively homogeneous population of viable
multicellular tumor spheroids with an average diameter less than 100 μm (Figure 1b-c)
was chosen to ensure drug

21

20.

This diameter

and oxygen diffusion into the spheroids. Spheroids were transferred to

PEG-MAL hydrogels for dosing, where bulk diffusion measurements of rhodamine 6G suggest small
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molecules diffuse through the 3D hydrogel at 2.5x10-6 cm2/s (data not shown), which means that the drug
will reach the cells within 10 seconds. Further, immunofluorescent staining of Ki67 expression revealed
that there were proliferating cells throughout the entire spheroid, suggesting there were no significant
nutrient or oxygen diffusion limitations within the 3D PEG hydrogel (Figure S1).
We previously found that breast cancer cells on stiffer substrates were more resistant to sorafenib
10,

so we included two different moduli for the 2D and 3D hydrogels (Figure S2). Although the effect of

altered proliferation across the biomaterials (Figure 1e-f) would confound comparisons of traditional IC50
calculations, it is accounted for in the GR50 calculation

15.

Therefore, the differences we report in drug

response are a direct result of ECM-driven resistance, independent of a growth advantage. In Figure 1e-f,
drug response is reported as a fold change in GR50 from the indicated condition compared to TCPS,
where red indicates resistance and blue indicates sensitivity compared to TCPS. Response to
doxorubicin did not vary significantly across geometry, modulus, or medium (with or without serum, varied
for the spheroid model only) in either cell line (Figure 1e-f, Figure S3). Response to temsirolimus was not
dependent on platform in the MDA-MB-231 cells, while in the SkBr3 cells, geometry and medium, but not
modulus, had a small, but significant, impact on GR50. However, sorafenib and lapatinib response varied
considerably across the biomaterial platforms, particularly in the MDA-MB-231 cells (Figure 1e-f, Figure
S3). It is notable that the SkBr3 response to sorafenib was only dependent on geometry, and not the
addition of serum, suggesting a unique role for the ECM in mediating drug response, independent of
exogenous mitogenic factors. A two-way analysis of variance (ANOVA) showed that the changes in
geometry and medium had a larger effect on total variance than the change in modulus as reported by
the percent of variation across biomaterial platforms (Table S1). Within each geometry, we observed no
significant difference in drug response at either stiffness, and we encourage the reader to view the bar
graphs and statistical analysis provided in the electronic supplementary information (Table S1, Figure
S3), indicating that cancer cell resistance to sorafenib and lapatinib was most sensitive to changes in
geometry within this modest stiffness range.

Gene expression is not responsible for ECM-driven differences in drug response
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We performed RNA-seq on MDA-MB-231 and SkBr3 cells cultured on TCPS, on 2D hydrogels,
as tumor spheroids, and as a tumor xenograft (Figure 2a). Hierarchical clustering of differentially
expressed genes first separated samples by the cell line, then by material platform (Figure S4). The
biomaterial platform dictated clustering within each cell line and dimensionality had greater influence on
clustering than stiffness. Gene expression on the 2D hydrogels (10 and 33 kPa) was similar for both cell
lines, and these samples are closely related to cells on TCPS. Toward understanding whether this was an
immediate effect of signals from the ECM or from selective growth of a subset of cells in different
environments, we also analyzed cells initially grown into spheroids, but then dissociated and cultured
back on TCPS for 24 hours. The gene expression profile from these dissociated spheroids was also
closely related to the other 2D conditions, indicating this expression was likely derived from the assay
platform, rather than the culture platform (Figure 2a).
Gene set enrichment analysis (GSEA) identified several significantly enriched pathways in one or
more of the biomaterials. For example, genes associated with the regulation of growth and receptorlinked signal transduction are upregulated in MDA-MB-231 cells on plastic compared to MDA-MB-231
cells in 3D spheroids (Figure 2b). While this is not an exhaustive list, cells on TCPS expressed more
cytokine and associated receptor genes and cells in the xenograft upregulated expression of ECM
components, particularly collagens and keratins. In Figure 2c and d, the normalized enrichment scores
are plotted as pairwise comparisons, enriched in the row condition over the column platform in red for
MDA-MB-231 cells and in blue for SkBr3 cells.

As expected, both cell lines upregulated genes

associated with growth regulation on TCPS compared to all the other conditions we examined (Figure 1ef, Figure 2b-c). Furthermore, the MDA-MB-231 xenograft tumors upregulated growth-related genes
compared to cells grown in vitro as spheroids, suggesting that the mouse host environment provided
additional growth cues (Figure 2c). However, both geometry and stiffness influenced surface receptor
linked signal transduction. For example, cells on TCPS universally showed enrichment for these genes
compared to the other biomaterials, and our spheroids showed enrichment over the 2D hydrogels in the
SkBr3 cells (Figure 2d).
We then used this expression data to determine if ECM-mediated drug response was a result of
changes in the gene expression of drug targets for lapatinib and sorafenib across the biomaterials (Figure

12

1e-f). We found no correlation between expression of these target genes and the GR 50 (Figure 2e,g).
However, both of these drugs are known to alter signaling of many other pathways, and a literature
search identified several known unintentional targets or resistance mechanisms for each drug

22-26

(Figure

2f,h). Although many of these genes showed little to no change in expression across the biomaterials, we
did note that AXL expression showed a slight positive trend, but not a significant correlation, with lapatinib
response in the MDA-MB-231 cells (Figure 2f). AXL has previously been shown to predict drug resistance
to ErbB targeted inhibitors in many cancer types

26,

but does not appear to significantly contribute to the

drug responses examined here.

Multiple linear regression reveals that using a MEK inhibitor with sorafenib is an effective
combination therapy
Since there were large differences in GR50 across the screening microenvironments, and known
drug targets were not responsible for ECM-mediated resistance, we hypothesized that plasticity in
intracellular signaling networks was responsible for the differential responses. We measured a panel of
phospho-proteins associated with RTK signaling at basal levels and in response to drug treatment across
the biomaterial ECMs. Here, we chose to closely examine sorafenib and lapatinib across material
platforms, and added temsirolimus to compare to a drug whose response was largely independent of
ECM (Figure 1e-f).
The basal levels of nearly every analyte were significantly lower in 3D than on 2D ECMs (Figure
3a-b), which matches growth and signal transduction gene signatures from our expression data (Figure
2c-d). As expected, drug treatment reduced the phosphorylation level of the intended targets (Figure 3cd). However, we only observed significant reduction in known targets and increases in adaptive pathways
in 2D, suggesting that the 3D environment suppresses drug efficacy through dampened signaling and
kinome rewiring. Dimensionality-dependent signaling differences were also present during direct
activation of the receptor by its cognate ligand. When stimulated with epidermal growth factor (EGF) on
TCPS, pEGFR was elevated within 5 minutes, and EGFR was internalized within an hour (Figure S5a-c).
When spheroids were encapsulated in 3D hydrogels, pEGFR and pHER2 were still stimulated at 5
minutes, but only modestly, and EGFR localization did not change with EGF stimulation (Figure S5a-f).
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Our lab has previously demonstrated the role of JNK in stiffness-dependent sorafenib resistance
10.

Because we observed increased pJNK in response to the drug treatments in both cell lines, we

hypothesized that JNK may mediate drug response across the biomaterials. Co-administration of JNK
inhibitor SP600125 sensitized the MDA-MB-231 cells to sorafenib on 2D biomaterials and as spheroids
with serum, as well as TCPS (Figure 3e). SP600125 only sensitized the SkBr3 cells in the spheroid and
2D hydrogel conditions, but not the stiff TCPS environment, perhaps a result of the very high increase in
pJNK in the sorafenib-treated SkBr3 cells in that environment (Figure 3g). We separately examined JNK
phosphorylation after treatment with doxorubicin, a non-targeted drug that provoked low variability across
platforms, and found that JNK signaling was still altered by drug treatment. This suggests that here JNK
may be caused by drug-induced stress, but does not significantly contribute ECM-mediated resistance
(Figure S6a-b). Further, the efficacy of the JNK inhibitor in the MDA-MB-231 spheroids in the 3D hydrogel
was mirrored in the simple TCPS assay, and did not need screening across biomaterials for discovery.
Thus, we sought to identify an efficacious combination therapy using this multi-environment screening
approach that could not be identified through simple TCPS screening.
Multiple linear regression (MLR) models revealed non-intuitive relationships between the
sorafenib-, lapatinib-, and temsirolimus-treated signaling and drug response data for both cell lines across
the biomaterials. This model was constructed from phosphorylation data of 10 analytes 4 hours after
targeted drug treatment at 15 conditions, including 3 drugs, and 5 biomaterial platforms per drug.
Although targeting the MEK/ERK pathway was not an obvious choice from the signaling data (Figure 3cd), these models revealed that variability in MEK phosphorylation was the key factor associated with
viability in response to drug treatment in MDA-MB-231 cells (Figure 3f,h). Here it is important to note that
the MLR output includes the contribution of each signaling analyte to drug response, and that while MEK
was identified as the key factor, other analytes have non-zero contributions to the model. To determine
the necessity of modeling cell response across several biomaterial platforms and drugs, we performed
subsequent analyses where we independently excluded either all 3D conditions (single cells, spheroids,
spheroids with serum) or 2 of the drugs (lapatinib and temsirolimus). Neither of these modified models
achieved significance (Figure S7a). Returning to our model that includes all 3 drugs in the MDA-MB-231
cells, we determined that each 3D condition could be excluded independently, but that TCPS, 2D
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biomaterials, and at least one 3D condition were necessary to predict MEK phosphorylation as a likely
mechanism of ECM-mediated resistance (Figure S7b).
We next co-administered both sorafenib and the MEK inhibitor PD0325901 to cells in the different
biomaterials. In both cell lines, there was no improved efficacy when co-treating sorafenib and
PD0325901 on TCPS (Figure 3e,g). However, both cell lines were sensitized to sorafenib when coadministered with PD0325901 in the 2D hydrogel and spheroid conditions (Figure 3e,g). This suggests
MEK may be a more physiological resistance mechanism to sorafenib, as SkBr3 cells did not show
significant variability of MEK across platforms, but were still responsive to co-treatment in our
biomaterials. Interestingly, the MDA-MB-231 cells are KRAS mutant, while the SkBr3 cells are not,
meaning this treatment is independent of both this mutation and their clinical subtype. Altogether, the
identification of MEK as an effective target for combination therapy was only realized through screening
across many biomaterials and using a systems approach to analyze a phospho-signaling dataset.
Likewise, the efficacy of the MEK inhibitor in combination with sorafenib was only achieved through
screening in the more complex 2D or 3D biomaterial microenvironments, and would be missed using
TCPS or via genetic analysis alone.

MEK inhibition improves sorafenib efficacy in vivo
Given the promising in vitro results with the MEK inhibitior, we tested PD0325901 as a
combination therapy with sorafenib in an in vivo model. MDA-MB-231 tumors were inoculated in the
mammary fat pad of NSG mice and allowed to grow for 7 days, at which point all mice had palpable
tumors. From days 7 to 21, we treated daily with one of four regimens: 1) vehicle control (DMSO), 2) 10
mg/kg sorafenib, 3) 10 mg/kg PD0325901, or 4) co-treatment of 10 mg/kg each sorafenib and
PD0325901 (Figure 4a). As combination therapies are often associated with increased adverse events

27,

we also included a fifth treatment group which received a lower dose of the combination therapy at 5
mg/kg each of sorafenib and PD0325901. All of these doses were found to be well tolerated by mice in
separate experiments (data not shown), although future work will need to better optimize the doses of this
combination therapy for optimal clinical efficacy. PD0325901 was the most effective single agent inhibitor
and, as predicted in the 2D hydrogel and spheroid screening models, co-treating mice with PD0325901
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and sorafenib had the most significant reduction in tumor burden, cellularity, and proliferation (Figure 4bd). In the lower concentration combination therapy (5 mg/kg each), reduction in tumor weight was
comparable to 10 mg/kg PD0325901 alone (Figure 4b). A two-way ANOVA showed that PD0325901
(Fvalue=54.7, p<0.001) contributed more to the decrease in tumor burden than sorafenib (Fvalue=8.2,
p<0.01). The combination therapy of sorafenib and PD0325901 additively decreased tumor burden
(Fvalue=0.3, p=0.6).

Discussion
By screening drug response across many ECMs, we identified that breast cancer cell response to
sorafenib (Ras/Raf/MEK/ERK targeted) and lapatinib (EGFR-HER2 targeted) was significantly dependent
upon the biomaterial environment (Figure 1e-f). Gene expression of known drug targets was unchanged
across the ECMs (Figure 2e-h), but a systems analysis of phospho-kinome signaling in response to drug
treatment across our different biomaterials revealed MEK as a key contributor to the variation in observed
ECM-mediated resistance (Figure 3f). Although the combination therapy did not improve drug response in
cells on TCPS, a MEK inhibitor in combination with sorafenib eliminated the matrix-mediated response in
biomaterials in vitro and reduced tumor burden in vivo (Figure 4e).
While most current literature examines signaling changes within a single platform

28-31,

we applied

MLR across five ECM conditions and three targeted drug treatments to determine which phosphoproteins varied significantly with ECM-mediated drug response. This approach captures multiple aspects
of the ECM that may contribute to drug response in vivo, including ECM stiffness, dimensionality, and
cell-cell contacts using both 2D and 3D biomaterials. Synthetic 2D biomaterials allow for the presentation
of full length proteins, while spheroids encapsulated in 3D better recapitulate tumor geometry.
Importantly, cells seeded onto 2D biomaterials or as single cells in 3D only resided in that platform for 24
hours, so they likely relied exclusively on the provided collagen I (2D) or RGD (3D) for biochemical
signals. However, breast cancer cells grown as spheroids upregulate ECM genes, such as fibronectin,
suggesting additional ECM cues might contribute to resistance

20.

Recent work has shown that the ECM-

mediated signaling can impart resistance to combined inhibition of PI3K and HER2

32,

but our method

identified that targeting two nodes in the same pathway, Raf with sorafenib and MEK with PD0325901, is
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a promising combination therapy for breast cancer. This non-intuitive co-treatment, which would not be
identified by screening on traditional TCPS, suggests a similar approach may be beneficial in identifying
combination therapies for kinome-targeting drugs, where adaptive resistance is frequently mediated by
the ECM 10, 12.
Combination therapies with MEK inhibition are effective in many cancer types

33-36.

In fact, MEK

inhibition is currently under evaluation in clinical trials because many cancers activate MEK signaling as a
form of acquired resistance

37.

Such combination therapies are often designed to limit adaptive survival

signaling, and generally target two distinct pathways. Interestingly, in our work, co-targeting MEK
improved sorafenib efficacy in vitro and in a pre-clinical in vivo tumor regression model, even though both
drugs target the same pathway (Figure 4b). Others have seen similar improved efficacy in HER2+ breast
cancer when co-treating the HER2-targeted drugs lapatinib and trastuzumab, suggesting that
combination therapies targeting the same pathway can have improved effects by overcoming acquired
resistance

38.

However, not all cells within a tumor contribute equally to drug response. Tumors are highly

heterogeneous and subpopulations can evade both cytotoxic and targeted therapeutics via upregulation
of drug transporters, mutations of drug targets, adaptive signaling, and other mechanisms

2, 39, 40.

Here we

identified the additive effect of co-dosing with sorafenib and a MEK inhibitor on bulk tumor properties, but
further work is necessary to understand the contribution of individual populations to resistance.
We measured a large panel of phospho-proteins to see if the biomaterial environment facilitated
phospho-signaling changes in response to the drug treatments that were associated with drug sensitivity
or resistance. In our soft 3D environments, basal and drug-stimulated signaling were significantly
suppressed, in agreement with other data in spheroids and on soft substrates
broad adaptive response

44, 45;

41-43.

JNK appears to be a

however, MLR identified MEK as the most significant driver of ECM-

mediated resistance to sorafenib. ERK is downstream of both the lapatinib and sorafenib targets, which
may explain why MEK/ERK signaling was so critical to drug response in our data. In agreement with our
findings, myeloid leukemia cells have a stiffness-dependent response to drugs, including sorafenib and a
MEK inhibitor, which target the RAF/MAPK pathway

46, 47.

resistance increased with increasing hydrogel stiffness

10,

stiffness is a significant driving force for drug resistance

We have previously shown that sorafenib

and many others have also demonstrated that

9, 10, 28, 29, 48-51.

Thus, we were surprised to find

17

that drug resistance was only minimally affected by stiffness within the modest range examined here
(Figure 1e-f). However, in our data, dimensionality contributed more to drug resistance than stiffness.
Previous work has similarly shown that cancer cell spheroids are more resistant to paclitaxel than a
monolayer 30, and the matrix-attached cells in spheroids are resistant to PI3K/mTOR inhibition 31.
Because cells are less able to form cell-matrix adhesions on soft versus stiff 2D substrates, and
in 3D versus 2D environments

52,

genes associated with integrin-mediated adhesion and cell-surface

receptor linked signal transduction are varied across our biomaterials (Figure 2b-d). Matrix adhesion via
integrins mediates survival and drug resistance through activation of survival signaling, such as FAK, Src,
and ERK 53-55. Disruption of cell adhesion can sensitize tumor cells to drug treatments

10, 32, 56-58.

In 3D, we

generally observed greater drug sensitivity for single cells compared to spheroids (Figure 1e-f), perhaps
because single cells have lower overall adhesions to surrounding cells and matrix

12.

Spheroids and

tumors can also exhibit multicellular drug resistance through either cell-cell contact-mediated signaling or
59,

drug diffusion limitations
matrix-attached cells

31.

and often co-targeting multiple pathways is required to sensitize the outer,

While our spheroid size was intentionally kept small to minimize diffusion

limitations, the cell-cell contact inherent to the spheroid structure may provide survival signaling, resulting
in increased resistance to the RTK-targeted drugs.
In our hands, gene expression of drug targets was relatively unchanged across our materials.
Previous work has reported significant changes in gene expression profiles of cell lines cultured in 2D and
3D laminin-rich ECM

60.

This is similar to our own data, where we observed that surface receptor linked

signal transduction genes vary with both geometry and stiffness, and are universally upregulated during
culture on TCPS compared to the other biomaterials (Figure 2b). Also, several ligand-receptor pairs were
co-expressed and enhanced in vivo, including BMP and IL6 signaling (Figure S8a-b). We found that
growth context determined the expression of cell surface receptors, while expression of the associated
ligands was dependent on the current assay platform and was more sensitive to stiffness.
Interestingly, both gene expression and drug sensitivity were regained when cells grown as
spheroids were dissociated and seeded back onto TCPS (Figure 2a, Figure S8). This demonstrates that
drug response in the timeframe we examined is dependent on the current environment and not
necessarily a result of stable genetic alterations or subpopulations resulting from a previous growth
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condition. In our gene expression data, the xenograft was the most distant from other samples for the
SkBr3 cells, but not for the MDA-MB-231 cells. This is likely due to the differences in length of time
required for the xenografts to reach a similar size. The MDA-MB-231 xenograft tumor reached 50 mm3
within 10 days, and the SkBr3 xenograft took 3 weeks to reach 50 mm3. In an in vivo microenvironment,
xenograft tumors derived from highly lung metastatic clones of the MDA-MB-231 breast cancer cell line
have a distinct ECM signature that up-regulates growth factor signaling including TGF-β and VEGF 61. We
conclude that although gene expression may be useful to inform patient treatment

62,

it was not sufficient

to predict in vitro or pre-clinical drug efficacy here.

Conclusions
Though the ECM can impart resistance to some RTK inhibitors (sorafenib and lapatinib), MLR
modeling of phospho-signaling identified combinatorial strategies to combat this resistance (Figure 4e).
This approach could provide insight into other anti-cancer drugs with varied clinical success, such as
neratinib

63, 64

and sunitinib

65, 66.

However, not all the drugs we tested showed ECM-dependent

responses, and response to a cytotoxic drug, such as doxorubicin, would have been predicted in a
simple, quick, cost-effective TCPS assay. It is therefore critical to weigh the monetary cost and time
burden of the screening approach against the potential benefits. The efficacy of the PD0325901 and
sorafenib combination therapy would not have been realized using only one screening environment or
without a systems biology analysis. We envision this approach can be used to identify drugs with poor in
vivo efficacy early in the drug development pipeline and identify novel drug combinations to overcome
ECM-induced resistance.
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Figures

Figure 1. Drug response is dependent upon the biomaterial screening platform. a. Schematic of biomaterial
drug screening platforms, including TCPS, 2D hydrogels linked with collagen I, and 3D hydrogels with RGD for cell
adhesion, either with encapsulated single cells or tumor spheroids. Each hydrogel condition was screened at two
different moduli (2D: 10 or 33 kPa, 3D: 3 or 5 kPa). b. Quantification of mean spheroid diameter for MDA-MB-231
spheroid growth in polyNIPAAM gels over 14 days. c. Viability of MDA-MB-231 spheroid after 14 days of growth in
polyNIPAAM, and encapsulation in 3 kPa 3D PEG-MAL hydrogel for 3 days. Green: live cells, red: dead cells. Scale:
100 μm. d. Experimental time investment required for the different screening platforms. Timeline displays preparation
time required for each system prior to treating with varying concentrations of drug. e-f. SkBr3 (e) and MDA-MB-231 (f)
proliferation after 3 days of culture (top row), and GR50 in response to doxorubicin, temsirolimus, sorafenib, and
lapatinib across the different biomaterial platforms. Red: increase from TCPS control (resistance compared to TCPS),
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blue: decrease from TCPS control (sensitivity compared to TCPS). TC: TCPS, 10: 10 kPa 2D hydrogel, 33: 33 kPa
2D hydrogel, 3: 3 kPa 3D hydrogel, 5: 5 kPa 3D hydrogel, +FBS: cells were treated in 10% serum-containing
medium. Unless noted by +FBS, all cells were treated with drugs in serum-free medium containing EGF and PDGFBB.

Figure 2. Expression of growth and signal transduction genes distinguishes screening platforms but does
not explain drug response. a. Clustering and normalized expression values of significantly differentially expressed
genes across the biomaterial platforms for MDA-MB-231 and SkBr3 cell lines. Genes were ordered by expression on
TCPS, and each cell line was independently filtered for the top 250 genes by maximum expression across all
platforms. All significantly differentially expressed genes (p<0.01) are shown in Figure S4. MDA-MB-231 order of
platforms: spheroids, xenograft, 2D hydrogels at 10 kPa, and 33 kPa, spheroids reseeded to TCPS, TCPS. SkBr3
order of platforms: xenograft, 2D hydrogels at 10 kPa, and 33 kPa, spheroids, spheroids reseeded to TCPS, TCPS.
Blue: low expression, red: high expression b. Representative gene set enrichment curves for regulation of growth
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(MDA-MB-231, TCPS over 3D spheroids) and cell surface receptor linked signal transduction (MDA-MB-231, TCPS
over 3D spheroids). c-d. Normalized enrichment scores in pairwise platform comparisons for (c) regulation of growth
(d) and cell surface receptor linked signal transduction. MDA-MB-231 comparisons are enriched in red and SkBr3
comparisons are in blue. Comparisons are shown as ROW condition over COLUMN (i.e., Top row shows MDA-MB231 enrichment on TCPS over other platforms). – indicates

no data. e-h. Expression of known targets for (e)

lapatinib and (g) sorafenib and previously published off-target genes for (f) lapatinib and (h) sorafenib across the
biomaterial platforms with linear correlations.
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Figure 3. Systems analysis reveals that MEK regulates ECM-mediated sorafenib efficacy. a-b. Basal p-ERK
(pT185/pY187), p-Akt (pS473), and p-JNK (pT183/pY185) signaling for MDA-MB-231 (a) and SkBr3 (b) cell lines
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across the five screening microenvironments. Black: TCPS, dark blue: 2D gel, green: 3D gel with single cells, teal: 3D
gel with spheroids, red: 3D gel with spheroids in serum. 2D hydrogel: 33 kPa, 3D hydrogel: 3 kPa. c-d. Phosphosignaling in response to drug treatment and GR50 for MDA-MB-231 (c) and SkBr3 (d) cell lines. TC: tissue culture
polystyrene, 2D: 2D PEG-PC hydrogel, 3D: single cells encapsulated in 3D hydrogels, Sp: spheroids encapsulated in
3D hydrogels, +: spheroids in 3D hydrogels in serum containing medium. Phospho-proteins measured include: CREB
(pS133), ERK (pT185/pY187), NFκB (pS536), JNK (pT183/pY185), p38 (pT180/pY182), STAT3 (pS727), STAT5A/B
(pY694/699), Akt (pS473), EGFR (pan Tyr), and MEK1 (pS222). Red: increase compared to vehicle control, blue:
decrease from vehicle control. e,g. Sorafenib GR50 alone or in combination with SP600125 (JNK inhibitor, 20 μM) or
PD0325901 (MEK inhibitor, 3 μM) for MDA-MB-231 (e) and (g) SkBr3 cell lines. Black: control, blue: SP600125, red:
PD0325901. f,h. MLR models of signaling data for MDA-MB-231 (f) and SkBr3 (h).

Figure 4. PD0325901 and sorafenib are an effective combination therapy to reduce in vivo tumor burden. a.
Schematic for tumor induction of the MDA-MB-231 cells, grown first for 7 days, followed by daily drug dosing for 14
days until a 21-day endpoint. b. Final tumor weight for each drug dosing condition (C: control, S: 10 mg/kg sorafenib,
PD: 10 mg/kg PD0325901, and co-dosing at either 5 mg/kg or 10 mg/kg of each therapeutic, p = 0.05; two-tailed ttest on log transformed data). c. Representative images for Ki67 staining in tumors and d. quantification of Ki67
positive cells in drug treatment groups (S/PD is the 10 mg/kg combination therapy). Scale bar is 50 μm. e. Screening
for ECM-mediated resistance in drugs like sorafenib can be used in combination with multiple linear regression
modeling to find combination therapies with the MEK inhibitor PD0325901. Error bars represent mean and SEM, N≥4.
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